Slide 1: Medexus Pharmaceuticals Q3 2026 Earnings
TSX: MDP | OTCQX: MEDXF Ken d’Entremont, CEO Brendon Buschman, CFO
Slide 2: Important Notes
Important Notes Go to the latest Medexus MD&A or AIF for full disclaimers Cautionary Note This presentation has been prepared by the management of Medexus Pharmaceuticals Inc. (“Medexus“ or the “Company”) for informational purposes based on the Company’s public disclosure. The sole purpose of this p
Slide 3: Improving lives one patient at a time
Improving lives one KEY HIGHLIGHTS patient at a US$108.3M 12% time FY2025 Revenue(1) 3 Year Revenue CAGR 15 Brands in Market 63% ✓ Focused on innovative ✓ Growing through increased Significant of Revenue is pharmaceutical products market performance, new near-term US driven in with strong market pro
Slide 4: Diversified Product Portfolio
Diversified Product Portfolio • Our portfolio features leading products that address a variety of diseases. • We provide innovative prescription and over the counter brands to patients and healthcare professionals, which we believe greatly enhances quality of life. • We actively evaluate new product
Slide 5: Proven Business Model
Proven Business Model • Medexus seeks to license or acquire products to address essential needs of patients and health care partners, leveraging our established North American sales force and infrastructure across a growing product portfolio. • We closely monitor a robust pipeline of opportunities t
Slide 6: North American Commercial Platform In Place
Strong Commercial North American Commercial Commercial • US$108.3M revenue (FY2025) Platform • • Established on-market portfolio $100M+ net revenue from GRAFAPEX within Platform In Place Medexus has built a 5 years after launch. • Generates meaningful operating cash flow(1) Combined national strong
Slide 7: GRAFAPEX (Treosulfan)
GRAFAPEX (Treosulfan) GRAFAPEX will drive significant revenue and operating cash flow growth First and only FDA-approved conditioning regimen for allogeneic hematopoietic stem Net Revenue Potential cell transplantation, or “allo-HSCT” in eligible patients with acute myeloid leukemia or myelodysplast
Slide 8: Trecondyv (Treosulfan)
Trecondyv (Treosulfan) Treosulfan successful launch and rapid growth in Canada Treosulfan was approved by Health Canada in June 2021, and Medexus commercially launched treosulfan in Canada under the brand name Trecondyv® in September 2021 Ex-Factory $ Sales by Fiscal Year Initiation of Current growt
Slide 9: Canadian Retrospective Study
Canadian Retrospective Study Princess Margaret hospital study shows a 56% less chance of all-cause mortality* after 2 years with treosulfan- over busulfan-based conditioning in HSCT for patients with MDS, as well as other positive findings, all generally consistent with the results from the pivotal
Slide 10: IXINITY®
IXINITY ® Delivering Long-Term Stability Medexus holds Global Rights to IXINITY® Currently indicated in adults and children with hemophilia B for control & prevention >$1 Billion* current US market with concentrated of bleeding episodes & for perioperative prescriber base. management. 4,000-5,000 to
Slide 11: Rasuvo® / Metoject
Rasuvo® / Metoject Mar ket Lea din g Product Strong Market Position MTX AutoPen TRX 120,000 Unique formulation of methotrexate 100,000 Autoinjector designed to treat rheumatoid arthritis and other auto immune disease. 80,000 60,000 Rasuvo has exclusive or advantaged status with many top payers/PBMs.
Slide 12: Rupall®
Rupall ® High-performing prescription allergy medication Oral solution (age 2yrs+) and tablets (teenagers/adults) with unique dual mode of action. Exclusivity Ended in January 2025 Competitive Landscape: Competitive generic activity is currently limited to the tablet form, while the pediatric soluti
Slide 13: Strong Track Record of Deal Execution
Strong Track Record of Deal Execution Rasuvo IXINITY Commercial expertise to seek out promising product Upfront cost Upfront cost opportunities in complementary therapeutic areas – Annual net sales Annual net sales aligned with our mission and purpose - ensuring a balance of products in different st
Slide 14: Selected Financial Results
Selected Financial Results All figures in US$M Revenue (US$M) (except multiples) Fiscal Q2 Fiscal Year $120 5 Year CAGR = 14% $108.1 $113.1 $108.3 2026 2025 2025 2024 $1 00 $79.7 $76.7 Revenue $24.7 $26.3 $108.3 $113.1 $80 $60 $55.5 Adjusted EBITDA (1) $4.4 $6.0 $20.2 $19.5 $4 0 $20 $0 Operating Cas
Slide 15: Capital Structure
Capital Structure ( $USD ) EV Calculation(1) Share Price (at Nov 11, 2025) C$2.68/ US$1.90 Shares Outstanding(2) 32.4M Credit Facility Provides Significant Flexibility Equity Market Capitalization (at Nov 11, 2025) $61.6M Net Debt (at Sept 30, 2025) $11.7M ➢ US$21 million term loan facility Enterpri
Slide 16: Key Investment Highlights
Key Investment Highlights Positioned to deliver near-term and long-term company value Diversified, durable, portfolio currently generating US$106.7M(1) in revenue, with positive Adj. EBITDA(2), and cash flow from operations Executing on significant year over year revenue and Adj. EBITDA(2) growth st
Slide 17: Company Contact Investor Relations
Company Contact Ken d’Entremont, CEO Phone: 905 676 0003 Email: Ken.Dentremont@medexus.com Brendon Buschman, CFO Phone: 416 577 6216 Email: Brendon.Buschman@medexus.com Investor Relations Frank Candido Direct Financial Strategies and Communication Inc. Phone: 514 969 5530 Email: Frank.Candido@direct
Slide 18: Important Notes
Important Notes See Medexus’s latest MD&A for more information Non-GAAP measures Company management uses, and this presentation refers to, non-GAAP measures, meaning financial measures that are not recognized under IFRS and do not have a standard meaning prescribed by GAAP in accordance with IFRS or